Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
First Claim
Patent Images
1. A suspension formulation for therapeutic use, comprising:
- a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics;
a dry particle formulation comprising a biomolecule dispersed in the vehicle; and
a surfactant incorporated in at least one of the vehicle and dry particle formulation.
2 Assignments
0 Petitions
Accused Products
Abstract
A suspension formulation for therapeutic use includes a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule dispersed in the vehicle, and a surfactant incorporated in at least one of the vehicle and dry particle formulation. A dry particle formulation includes an interferon, a buffer, a surfactant, and one or more stabilizers selected from the group consisting of a carbohydrate, an antioxidant, and an amino acid.
-
Citations
28 Claims
-
1. A suspension formulation for therapeutic use, comprising:
-
a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics;
a dry particle formulation comprising a biomolecule dispersed in the vehicle; and
a surfactant incorporated in at least one of the vehicle and dry particle formulation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A dry particle formulation comprising:
an interferon, a buffer, a surfactant, and one or more stabilizers selected from the group consisting of a carbohydrate, an antioxidant, and an amino acid. - View Dependent Claims (15, 16, 21, 24, 25)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
22. (canceled)
-
23. (canceled)
-
26. (canceled)
-
27. An implantable delivery device comprising:
-
a suspension formulation comprising a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising an interferon dispersed in the vehicle, and a surfactant incorporated in at least one of the vehicle and dry particle formulation; and
a reservoir containing the suspension formulation in an amount sufficient to provide continuous delivery of the interferon in a therapeutically effective dose in an environment of use over at least one month.
-
-
28. (canceled)
Specification